logo

Acceleron Pharma, Inc (XLRN)



Trade XLRN now with
  Date
  Headline
10/27/2021 7:27:22 AM Acceleron Expects To Report Royalty Revenue Of $32.0 Mln from Net Sales Of REBLOZYL In Q3
9/30/2021 7:13:03 AM Merck To Buy Acceleron For $180/Shr Cash For About Total Equity Value Of $11.5 Bln
5/19/2021 8:26:07 AM Acceleron Presents Interim Results From Open-label Extension Of PULSAR Phase 2 Trial Of Sotatercept At ATS 2021
5/19/2021 8:18:20 AM Acceleron Pharma Presents Preliminary Interim Data From SPECTRA Phase 2 Trial Of Sotatercept
5/12/2021 11:02:05 AM Acceleron Announces Presentations On REBLOZYL At 2021 European Hematology Association Virtual Congress
4/5/2021 7:14:27 AM Acceleron Announces Clinical Trial Updates, Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension
2/4/2021 7:56:42 AM Acceleron Pharma Expects About $23.0 Mln In Royalty Revenue For Q4
2/28/2018 7:56:52 AM RBC Capital Markets Is Increasing Acceleron Pharma, Inc (XLRN) FY18 Rev. Estimate To 40.97 M From 39.40 M
2/28/2018 7:48:47 AM RBC Capital Markets Is Cutting Acceleron Pharma, Inc (XLRN) FY18 Estimate To -2.83 From -2.73